Theravance Biopharma (NASDAQ:TBPH) Sets New 12-Month High – What’s Next?

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares hit a new 52-week high on Tuesday . The stock traded as high as $20.35 and last traded at $20.40, with a volume of 199677 shares trading hands. The stock had previously closed at $19.65.

Wall Street Analysts Forecast Growth

TBPH has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. HC Wainwright lifted their price target on shares of Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Oppenheimer assumed coverage on Theravance Biopharma in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price target on the stock. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Finally, BTIG Research upped their target price on Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, November 26th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Theravance Biopharma presently has an average rating of “Buy” and a consensus price target of $27.80.

Theravance Biopharma Price Performance

The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of 35.67 and a beta of 0.14. The stock has a fifty day moving average of $18.17 and a two-hundred day moving average of $14.84.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.10. The company had revenue of $19.99 million during the quarter, compared to analysts’ expectations of $19.89 million. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. On average, research analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total transaction of $582,506.25. Following the completion of the transaction, the senior vice president directly owned 277,695 shares in the company, valued at $5,206,781.25. This trade represents a 10.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of TBPH. Vanguard Group Inc. lifted its position in shares of Theravance Biopharma by 2.5% during the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after purchasing an additional 54,152 shares in the last quarter. Geode Capital Management LLC increased its stake in Theravance Biopharma by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company’s stock valued at $9,863,000 after buying an additional 3,416 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Theravance Biopharma by 6.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 766,704 shares of the biopharmaceutical company’s stock worth $11,193,000 after buying an additional 44,634 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in shares of Theravance Biopharma during the 3rd quarter worth approximately $10,611,000. Finally, Bank of America Corp DE boosted its stake in shares of Theravance Biopharma by 16.5% in the 2nd quarter. Bank of America Corp DE now owns 539,645 shares of the biopharmaceutical company’s stock worth $5,952,000 after buying an additional 76,417 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.